Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Phase 1 Recruiting
21 enrolled
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Phase 1 Recruiting
60 enrolled
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Phase 1 Recruiting
20 enrolled
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Phase 2 Recruiting
115 enrolled
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
Phase 2 Recruiting
30 enrolled
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Recruiting
200 enrolled
FIL_CTCL
Recruiting
400 enrolled
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Phase 2 Recruiting
48 enrolled
FLASH2
Phase 3 Recruiting
80 enrolled
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
Phase 2 Recruiting
50 enrolled
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Phase 2 Recruiting
58 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Recruiting
2,000 enrolled
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Phase 2 Recruiting
34 enrolled
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Phase 1 Recruiting
127 enrolled
Photopheresis in Early-stage Mycosis Fungoides
Phase 2 Recruiting
74 enrolled
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
46 enrolled
Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
Recruiting
15 enrolled
A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab
Recruiting
100 enrolled
SKINERGY
Recruiting
840 enrolled
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
Phase 1 Recruiting
10 enrolled
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Recruiting
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Phase 2 Recruiting
30 enrolled
Registry of Older Patients With Cancer
Recruiting
3,000 enrolled
A Registry for People With T-cell Lymphoma
Recruiting
1,000 enrolled
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Phase 1/2 Recruiting
85 enrolled
Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides
Recruiting
60 enrolled